These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26409276)

  • 1. The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.
    Knight GM; Colijn C; Shrestha S; Fofana M; Cobelens F; White RG; Dowdy DW; Cohen T
    Clin Infect Dis; 2015 Oct; 61Suppl 3(Suppl 3):S147-54. PubMed ID: 26409276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study.
    Salvatore PP; Becerra MC; Abel zur Wiesch P; Hinkley T; Kaur D; Sloutsky A; Cohen T
    J Infect Dis; 2016 Jan; 213(1):149-55. PubMed ID: 26092854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis.
    Mnyambwa NP; Kim DJ; Ngadaya ES; Kazwala R; Petrucka P; Mfinanga SG
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2021-2028. PubMed ID: 28593375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fitness of acquired drug resistant Mycobacterium tuberculosis isolates from DOTS compliant patients.
    Bhatter P; Mistry N
    Tuberculosis (Edinb); 2013 Jul; 93(4):418-24. PubMed ID: 23615069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness.
    Cohen T; Murray M
    Nat Med; 2004 Oct; 10(10):1117-21. PubMed ID: 15378056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives.
    Gygli SM; Borrell S; Trauner A; Gagneux S
    FEMS Microbiol Rev; 2017 May; 41(3):354-373. PubMed ID: 28369307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prisons as ecological drivers of fitness-compensated multidrug-resistant Mycobacterium tuberculosis.
    Gygli SM; Loiseau C; Jugheli L; Adamia N; Trauner A; Reinhard M; Ross A; Borrell S; Aspindzelashvili R; Maghradze N; Reither K; Beisel C; Tukvadze N; Avaliani Z; Gagneux S
    Nat Med; 2021 Jul; 27(7):1171-1177. PubMed ID: 34031604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations conferring resistance to first- and second-line drugs in multidrug-resistant Mycobacterium tuberculosis clinical isolates in southeast Mexico.
    Zenteno-Cuevas R; Xochihua-Gonzalez O; Cuevas-Córdoba B; Victoria-Cota NL; Muñiz-Salazar R; Montero H; Hamsho-Díaz P; Lauzardo M
    Int J Antimicrob Agents; 2015 Jun; 45(6):671-3. PubMed ID: 25819011
    [No Abstract]   [Full Text] [Related]  

  • 9. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.
    Gagneux S; Long CD; Small PM; Van T; Schoolnik GK; Bohannan BJ
    Science; 2006 Jun; 312(5782):1944-6. PubMed ID: 16809538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic characterization of multi-drug-resistant Mycobacterium tuberculosis isolates in Myanmar.
    Aye KS; Nakajima C; Yamaguchi T; Win MM; Shwe MM; Win AA; Lwin T; Nyunt WW; Ti T; Suzuki Y
    J Infect Chemother; 2016 Mar; 22(3):174-9. PubMed ID: 26806152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture.
    O'Sullivan DM; McHugh TD; Gillespie SH
    J Med Microbiol; 2010 Dec; 59(Pt 12):1533-1535. PubMed ID: 20724506
    [No Abstract]   [Full Text] [Related]  

  • 12. Competitive fitness of
    Kodio O; Georges Togo AC; Sadio Sarro YD; Fane B; Diallo F; Somboro A; Degoga B; Kone M; Coulibaly G; Tolofoudje M; Bane S; Sanogo M; Kone B; Coulibaly N; Dabitao D; Baya B; Maiga M; Bougoudogo F; Samake F; Dao S; Doumbia S; Diallo S; Diarra B
    Int J Mycobacteriol; 2019; 8(3):287-291. PubMed ID: 31512606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid resistance and the future of drug-resistant tuberculosis.
    Cohen T; Becerra MC; Murray MB
    Microb Drug Resist; 2004; 10(4):280-5. PubMed ID: 15650371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
    Alame-Emane AK; Xu P; Pierre-Audigier C; Cadet-Daniel V; Shen X; Sraouia M; Siawaya JF; Takiff H; Gao Q; Gicquel B
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):679-84. PubMed ID: 25946359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
    Zhang Z; Pang Y; Wang Y; Liu C; Zhao Y
    Int J Antimicrob Agents; 2014 Mar; 43(3):231-5. PubMed ID: 24439458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.
    Kim HJ; Kwak HK; Lee J; Yun YJ; Lee JS; Lee MS; Min SY; Park SK; Kang HS; Maeng YH; Kim SY; Kim SY; Kook YH; Kim YR; Lee KH
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):98-103. PubMed ID: 22236853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping and molecular characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from China.
    Zhang Z; Lu J; Liu M; Wang Y; Qu G; Li H; Wang J; Pang Y; Liu C; Zhao Y
    J Infect; 2015 Apr; 70(4):335-45. PubMed ID: 25485999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution and transmission of antibiotic resistance is driven by Beijing lineage
    Silcocks M; Chang X; Thuong Thuong NT; Qin Y; Minh Ha DT; Khac Thai PV; Vijay S; Anh Thu DD; Ngoc Ha VT; Ngoc Nhung H; Huu Lan N; Quynh Nhu NT; Edwards D; Nath A; Pham K; Duc Bang N; Hong Chau TT; Thwaites G; Heemskerk AD; Chuen Khor C; Teo YY; Inouye M; Ong RT-H; Caws M; Holt KE; Dunstan SJ
    Microbiol Spectr; 2023 Dec; 11(6):e0256223. PubMed ID: 37971428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mycobacterium tuberculosis mutants with multidrug resistance: history of origin, genetic and molecular mechanisms of resistance, and emerging challenges].
    Prozorov AA; Zaĭchikova MV; Danilenko VN
    Genetika; 2012 Jan; 48(1):5-20. PubMed ID: 22567849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of reasons of the MDR M. tuberculosis strains dissemination by analysis of the rifampicin and/or isoniazid resistant isolates].
    Sivkov AIu; Boldyrev AN; Azaev MSh; Bodnev SA; Medvedeva EV; Baranova OI; Ivlev-Dantau AP; Blinova LN; Pasechnikov AD; Tat'kov SI
    Mol Gen Mikrobiol Virusol; 2006; (2):20-5. PubMed ID: 16755998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.